Huons Acquires 31.5% Stake in PanGen Biotech to Build Biopharma CDMO Capability

BioNTech Acquires Biotheus

February 3, 2025

Biotechnology

BioNTech SE has completed the acquisition of clinical-stage biotechnology company Biotheus for $800 million in cash and ADS consideration plus up to $150 million in milestone payments. The deal gives BioNTech full global rights to BNT327 and Biotheus' antibody platform, and adds a local R&D hub and biologics manufacturing facility in China to BioNTech's network to support its oncology strategy.

Genmab Acquires ProfoundBio for $1.8 Billion

April 3, 2024

Biotechnology

Genmab A/S will acquire clinical-stage biotech ProfoundBio, Inc. in an all-cash transaction valued at USD 1.8 billion to obtain worldwide rights to ProfoundBio's pipeline of antibody-drug conjugates (ADCs), including rinatabart sesutecan (Rina-S). The deal is intended to broaden and strengthen Genmab's oncology and ADC capabilities and is expected to close in the first half of 2024, subject to customary conditions.

Biogen Acquires Human Immunology Biosciences for up to $1.8B

May 22, 2024

Biotechnology

Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.

Servier Acquires Symphogen A/S from Novo Holdings and Other Owners

April 3, 2020

Biotechnology

Servier has acquired 100% of the share capital of Symphogen A/S from Novo Holdings and the remaining owners, taking ownership of the Danish therapeutic antibody discovery and early biologics development company. The deal brings Symphogen’s antibody discovery platform and CMC biologics development capabilities into Servier’s oncology and immuno-oncology R&D efforts to strengthen its biologics pipeline and development capacity.

Merck Acquires Pandion Therapeutics

February 25, 2021

Biotechnology

Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.